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Conclusion. These findings illustrate that bradykinin playsEffects of ACE inhibition and bradykinin antagonism on car-
an important role for the beneficial effect of Ramipril in pre-diovascular changes in uremic rats.
venting (and potentially reversing) abnormal cardiovascularBackground. Cardiovascular death continues to be a major
structure in uremic hypertensive rats.problem in renal failure. Structural abnormalities of the heart
and the vasculature contribute to the increased cardiovascular
risk. They are ameliorated by angiotensin-converting enzyme
(ACE) inhibitors, but because of the nonspecifity of ACE
Increased cardiovascular mortality continues to be aninhibition, it is uncertain whether the beneficial effect is medi-
unresolved problem of chronic renal failure. The genesisated by interfering with angiotensin II (Ang II) or by modulat-
ing other effector systems, for example, bradykinin. is multifactorial, but abnormalities in cardiovascular
Methods. To assess a potential role of bradykinin, subtotally structure play a major role [1]. The administration of
nephrectomized Sprague-Dawley rats (SNX) received either
angiotensin-converting enzyme inhibitors (ACEi) sig-the ACE inhibitor Ramipril (Rami, 0.2 mg/kg body weight
nificantly improves the structural abnormalities in exper-p.o.), the specific B2 bradykinin receptor antagonist Hoe140
(0.2 mg/kg body weight, s.c.), or a combination of both, and imental and clinical studies [2, 3]. In particular, in experi-
were compared to sham-operated controls. To separately assess mental renal failure left ventricular hypertrophy (LVH),
the effect of Ramipril on development and reversal of struc- interstitial fibrosis and arteriolar wall thickening weretural abnormalities, animals were either treated from the third
prevented by ACEi, whereas reduced myocardial capil-day after SNX or from the fourth week after SNX onward
lary supply was not affected [4]. Furthermore, in a con-(0.01 mg/kg body weight, p.o.).
Results. Heart and aorta were evaluated by morphometric trolled study, the administration of ACEi was shown to
and stereologic techniques. The weight of the perfused left reverse LVH in dialyzed patients [3].
ventricle, as an index of cardiac hypertrophy, was significantly
In several experimental models of hypertension, it washigher in untreated SNX. While it was significantly lower in
shown that ACEi could interfere with vascular remodel-animals with early and late Ramipril treatment, the beneficial
effect was completely antagonized by Hoe140. The wall-to- ing. This action was, at least in part, independent of their
lumen ratio of intramyocardial arterioles was significantly hypotensive action [5], since even subhypotensive doses
higher in untreated SNX compared with controls, but failed of ACEi were effective [6]. The effect of ACEi was alsoto be modified by administration of either Ramipril or Hoe140.
greater than that seen with equihypotensive doses ofIn the heart, the intercapillary distance was significantly higher
in SNX, but it was not lowered by either early or late Ramipril alternative antihypertensive agents [7].
or Hoe140 treatment. Treatment of SNX with Hoe140 alone, Although ACEi were introduced primarily with the in-
however, resulted in a marked further increase in intercapillary tention to reduce the generation of angiotensin II (Ang II),distance. The wall thickness of the aorta was significantly higher
the interpretation of these results remained equivocalin SNX than in controls; early and late Ramipril treatment
because of the restricted specificity of ACEi. In particular,prevented such increase, and this effect was antagonized by
Hoe140. it was uncertain to what extent the effect was explained
by accumulation of bradykinin secondary to inhibition
of the kininase II activity of the ACE. Bradykinin influ-Key words: hypertension, renin system, heart, aorta, Ramipril, subtotal
nephrectomy. ences proliferation and protein synthesis in various tis-
sues [8], either per se or secondary to activation of media-
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potential role of accumulation of bradykinin in the bene- tioned previously in this article). Blood samples were
taken, and the viscera were rinsed with 10% dextranficial cardiovascular effects of ACEi. To this end, we
compared the effects of the ACEi Ramipril, the specific solution containing 0.5 g/L Procain-HCl for two minutes.
Ten seconds after starting the aortic perfusion, the venaB2 receptor antagonist Hoe140, and their combination
on the following indices: LVH (as reflected by absolute cava was incised to drain the blood. After dextran infu-
sion, the vascular system was perfused with 0.2 mol/Land relative left ventricular weight), myocardial capillary
density (as reflected by length density and intercapillary phosphate buffer containing 3% glutaraldehyde for 12
minutes. After the perfusion, the heart of each animaldistance), geometry of intramyocardial arterioles, and
wall thickness of the aorta. was taken out for determination of weight and volume
and tissue sampling, and section staining was performed
according to the orientator method [4, 12]. Uniformly
METHODS
random sampling was achieved by preparing a set of
Animals equidistant slices of the left ventricle and the interven-
tricular septum with a random start. Two slices wereForty-eight male Sprague-Dawley rats (weighing 200 g;
Invanovas Co., Kisslegg, Germany) were housed in sin- selected by area-weighted sampling and processed using
the orientator method [12]. Eight pieces of the left ven-gle cages at a constant temperature (208C) and humidity
(25%). The animals were given a high-protein, low-salt tricular muscle, including the septum, were prepared and
afterward embedded in Epon-Araldite. Semithin sec-diet containing 40% protein and 0.6% NaCl (Altromin
C 1002/C 1036; Altromin Co., Lage, Germany). After tions (1 mm) were stained with methylen-blue and basic
fuchsin and were examined by light microscopy withthree days of adaptation, the animals were randomly
allocated to partial nephrectomy (SNX) or sham opera- oil immersion and phase contrast at a magnification of
1000:1.tion (sham). Blood pressure (BP) was measured at the
beginning of the experiment and then every two weeks The aorta was cut into a 2 mm thick piece at a certain
distance from the aortic arch. After embedding (dis-by tail plethysmography.
cussed previously in this article), semithin sections were
Renal ablation prepared and stained as described.
First, the right kidney was removed under Ketamin/
Stereological analysisDiazepam anesthesia (100 mg/kg or 2.5 mg/kg, respec-
tively). Seven days later, the left kidney was partially Quantitative stereology: Heart. All investigations were
performed in a blinded manner (that is, the observerresected by removing a quantity corresponding to two
thirds of the weight of the resected right kidney from was unaware of the study group to which the animal
belonged). Per animal, eight random samples of differ-the left cortex. The control animals were sham operated
by decapsulating the kidney. Special care was taken to ently oriented left ventricular sections were investigated
using the orientator method [4, 12].avoid damage to the adrenals.
In brief, the length density (LV) of capillaries, that is,
Experimental protocol the length of capillaries per unit tissue volume, and the
volume density (VV) of cardiac capillaries, defined as theThe animals were randomly allocated to the following
experimental groups (N 5 6 to 9 animals per group; volume of capillaries per unit myocardial tissue volume,
were measured in eight systematically subsampled areasadministration of medication was started three days post-
operatively): (1) sham-operated controls (controls), (2) per section (57,600 mm2) using a Zeiss eyepiece with 100
points for point counting. The length density of myocar-untreated subtotally nephrectomized rats (SNX), (3)
subtotally nephrectomized rats 1 0.1 mg/kg body weight dial capillaries (LV) was determined using the equation
LV 5 2 QA, where QA is area density (for example, theRamipril (SNX 1 Rami1), (4) subtotally nephrecto-
mized rats 1 0.1 mg/kg body weight Ramipril p.o. 1 number of capillary transsects per area of myocardial
reference tissue) [13].0.2 mg/kg body weight Hoe140 subcutaneously (SNX 1
Rami1 1 Hoe140), and (5) subtotally nephrectomized Volume density (VV) of capillaries, interstitial tissue,
and myocytes was obtained using the point-countingrats 1 0.2 mg/kg body weight Hoe140 subcutaneously
(SNX 1 Hoe140). In an ancillary experiment, medication method [13] according to the equation PP 5 VV, where
PP is point density. Reference volume was the total myo-was started five weeks postoperatively: (6) subtotally
nephrectomized rats 1 0.2 mg/kg body weight Ramipril cardial tissue (exclusive of noncapillary vessels, that is,
arterioles and veins). Intercapillary distance, defined asp.o. (SNX 1 Rami2).
Eight weeks after the second operation, the experi- the distance between the centers of two adjacent intra-
myocardial capillaries, was calculated according to ament was terminated by perfusion fixation. At the end
of the experiment, the abdominal aorta was catheterized modification of the formula of Henquell and Honig [4].
Wall thickness and lumen diameter of intramyocardialunder Ketamin/Diazepam anesthesia (doses as men-
Amann et al: Bradykinin and uremic cardiovascular changes 155
Table 1. Chemistry
SCr Surea K Ca PHb
Groups g/dL mmol/Lmg/dL
Controls (N 5 8) 0.5860.05 42.4615.0 15.161.28 4.4060.98 2.4860.13 2.6061.13
Untreated SNX (N 5 7) 0.7460.05a 82.7620.4a 14.860.58 4.060.23 2.5760.03a 2.4160.16
SNX 1 Rami1 (N 5 7) 0.7460.07a 95.7639.7a 14.860.42 4.3460.43 2.5460.09 2.2860.17
SNX 1 Rami1 1 Hoe140 (N 5 7) 0.7260.03a 83.5620.3a 15.260.61 4.1560.19 2.5860.06a 2.3760.32
SNX 1 Hoe140 (N 5 8) 0.7260.04a 69.9612.3a 16.560.84 4.0760.34 2.5760.04a 2.2060.37
SNX 1 Rami2 (N 5 8) 0.7660.04a 78.669.16a 16.160.82 4.0660.31 2.5960.04a 2.2560.35
Analysis of variance P , 0.05 P , 0.05 NS NS P , 0.05 NS
Abbreviations are: SCr, serum creatinine; Surea, serum urea; Hb, hemoglobulin; SNX, subtotally nephrectomized rats; Rami1, Ramipril. Rami1 is defined as treatment
with 0.1 mg/kg body weight Ramipril from day 3 after SNX onward; Rami2 is treatment with 0.2 mg/kg body weight Ramipril from week 4 after SNX onward.
aP , 0.05 vs. sham-operated control
Table 2. Blood pressure, body weight and weight of left ventricle after perfusion
Body weight Systolic blood pressure Left ventricular weight Left ventricular weight/
Groups g mm Hg mg body weight ratio mg/g
Controls (N 5 8) 471621 112617 943651 2.0160.12
Untreated SNX (N 5 8) 456640 125622 10526109a 2.3260.27a
SNX 1 Rami1 (N 5 7) 406643a,b 92615b 8956132b 2.2060.15
SNX 1 Rami1 1 Hoe140 (N 5 9) 414632a,b 10467b 1027697a,c 2.4960.26a,c
SNX 1 Hoe140 (N 5 9) 453618 124613 1100693a,c,d 2.4260.14a,c
SNX 1 Rami2 (N 5 7) 409631a,b 104614b 9346139b 2.2860.23a
Analysis of variance P , 0.05 P , 0.05 P , 0.05 P , 0.05
Rami1 is defined as treatment with 0.1 mg/kg body weight Ramipril from day 3 after SNX onward; Rami2 is treatment with 0.2 mg/kg body weight Ramipril from
week 4 after SNX onward. Abbreviations are in Table 1.
aP , 0.05 vs. sham-operated control
bP , 0.05 vs. untreated SNX
cP , 0.05 vs. SNX 1 Rami1
dP , 0.05 vs. SNX 1 Rami2
arteries were determined planimetrically using a semiau- [15]. Hemoglobin concentrations were not significantly
tomatic image analyzing system (Videoplan, Kontron different between the groups. Systolic BP tended to be
Co., Eching, Germany). Wall-to-lumen ratio was calcu- higher in untreated SNX than in controls, but this was
lated by dividing wall thickness and lumen diameter [4]. not statistically significant. BP was significantly lower
Quantitative stereology: Aorta. Wall thickness, lumen in both Ramipril-treated SNX groups compared with
diameter, lumen, and wall area were measured on semi- untreated SNX. This difference was almost completely
thin sections in five to eight animals per group using obliterated by concomitant treatment with Hoe140. In
planimetry, as described in detail [4, 14]. agreement with previous results [4, 15], body weight was
significantly lower in both Ramipril-treated SNX groups.
Statistics The left ventricular weight (after perfusion) was signifi-
All data are expressed as mean 6 SD. Kruskal–Wallis cantly higher in untreated SNX than in controls. This
test and one-way analysis of variance (ANOVA), respec- increase was significantly less with early and late Rami-
tively, were chosen for analysis of variance, followed by pril treatment, respectively. An increased left ventricular
the least-significant difference test to assess the differ- weight was seen, however, in animals with Ramipril plus
ences between the groups. Results were considered sig- concomitant treatment with Hoe140 or treatment with
nificant if P , 0.05. Hoe140 alone.
Intramyocardial arterioles
RESULTS (morphometrical measurements)
Animal data Although the mean luminal diameters were not signifi-
cantly different, the wall thickness was significantly ele-The mean serum creatinine concentrations in SNX
animals were only moderately, but significantly elevated vated in SNX animals (Table 3 and Figs. 1 A, B and 2).
This was not influenced by treatment with Ramiprilcompared with sham-operated controls (Tables 1 and 2).
This degree of subtotal nephrectomy reduces the neph- (starting either early or late), Hoe140, or their combina-
tion (Fig. 1 C, D). The changes of the wall-to-lumenron number from around 45,000 to 21,700 per kidney
Amann et al: Bradykinin and uremic cardiovascular changes156
Table 3. Morphometrical measurements of intramyocardial arterioles
Wall-to-lumenWall thickness Lumen diameter
ratio
Groups lm lm/lm 3 1023
Controls (N 5 9) 2.5661.40 41.463.93 63631
Untreated SNX (N 5 8) 3.4962.05a 42.266.74 86648a
SNX 1 Rami1 (N 5 6) 3.3162.58a 41.062.58 85664a
SNX 1 Rami1 1 Hoe140 (N 5 9) 3.7661.74a 44.565.17 89647a
SNX 1 Hoe140 (N 5 9) 3.2661.86a 43.164.77 79645a
SNX 1 Rami2 (N 5 7) 3.5961.39a 47.865.33 86643a
Analysis of variance P , 0.05 NS P , 0.05
NS is not significant.
Rami1 is treatment with 0.1 mg/kg body weight Ramipril from day 3 after SNX onward; Rami2 is treatment with 0.2 mg/kg body weight Ramipril from week 4
after SNX onward.
aP , 0.05 vs. sham-operated control
ratio went in parallel. As shown in Figure 2, systematic mm2 in controls; media area 1.37 6 0.15 mm2 in SNX
vs. 1.39 6 0.33 mm2 in controls). In both of the Ramiprilsampling errors resulting from rarefaction of small arteri-
oles or from a systematic failure to measure arterioles of treatment groups, however, the media area was lowest.
a specific size category are excluded, since the cumulative
frequency as a function of luminal diameter remained
DISCUSSION
unchanged (Fig. 2).
These results clearly show that in this model of subto-
tally nephrectomized rat, treatment with the ACE inhibi-Intercapillary distance
tor Ramipril interfered with the development of the fol-Figure 3 shows that the intercapillary distance was sig-
lowing pathologies: increased left ventricular mass,nificantly higher in untreated and Hoe140-treated SNX
reduced capillary density, and aortic wall thickening.compared with sham-operated controls. It was not sig-
After ACEi, these indices were lower than in untreatednificantly affected by treatment with Ramipril alone or
SNX even when Ramipril treatment was delayed, consis-in combination with Hoe140. Conversely, the length den-
tent with (but not definite proof for) potential reversal.sity (mm/mm3) was significantly less in untreated and
In contrast, thickening of the wall of intramyocardialHoe140-treated SNX compared with controls (3.395 6
arterioles was not affected by ACEi. The beneficial ef-558 and 3.303 6 576 vs. 4.796 6 913); it was not signifi-
fects of the ACEi on LVH and aortic wall thickeningcantly affected by early and late Ramipril (4.224 6 887
were antagonized by the specific bradykinin B2 receptorand 4.318 6 914) or the combination treatment (4.089 6
antagonist HOE 140. These observations suggest that716).
the beneficial effect of ACEi is mediated, at least in
Aorta part, via accumulation of bradykinin. The reduction in
myocardial capillary supply was further enhanced byMean wall thickness (Fig. 4) as well as the mean wall
treatment with the bradykinin receptor blocker HOEthickness/body weight ratio were significantly higher in
140, suggesting a potential role of bradykinin on myocar-untreated SNX (125.8 6 7.4 mm and 0.27 6 0.01 mm/g)
dial capillary growth. This finding is in line with previousthan in controls (101.8 6 12.9 mm and 0.22 6 0.02 mm/g,
findings in spontaneously hypertensive rats [16]. In con-respectively). Aortic wall thickening was due to an in-
trast, wall thickening of intramyocardial arterioles re-crease in aortic smooth muscle cell number (Fig. 5 A, B)
mained unaffected by either Ramipril or Hoe140, a find-and was no longer present with continuous Ramipril
ing that argues for the involvement of other mediatortreatment (Rami1, 88.6 6 6.5 mm and 0.22 6 0.03 mm/g;
systems, for example, endothelin 1 (ET-1) [17].Fig. 5C). In contrast, in animals additionally treated with
Several aspects of design and methodology deserveHoe140 (112.1 6 19.4 mm and 0.27 6 0.05 mm/g; Fig.
comment. In the present study, resection of renal (corti-5D) or with Hoe140 alone (111.6 6 11.4 mm and 0.25 6
cal) mass, and by implication reduction of nephron num-0.02 mm/g), as well as in animals with late Ramipril treat-
ber, was deliberately kept modest in order to avoid anment (Rami2) starting four weeks after SNX (98.6 6
important role of confounding factors such as severe13.9 mm and 0.25 6 0.04 mm/g), a beneficial effect could
hypertension, anemia, and metabolic acidosis. In viewnot be observed.
of this, it is therefore even more remarkable that weThere was no significant difference in aortic lumen and
found pronounced abnormalities of cardiovascular struc-media cross-sectional areas. This was true for absolute
tures. For unknown reasons, Ramipril caused a signifi-values as well as for values factored for body weight
(lumen area 4.71 6 0.46 mm2 in SNX vs. 4.53 6 0.76 cant reduction in body weight, in agreement with previ-
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Fig. 1. Changes of intramyocardial arterioles
in renal failure: Effect of angiotensin-convert-
ing enzyme inhibition (ACEi) and bradykinin
antagonism. Semithin sections (magnification,
1:600). The wall thickness is significantly
higher in untreated (B), ACEi (C), and
ACEi 1 Hoe140-treated (D) SNX compared
with sham-operated controls (A).
Fig. 5. Effects of Ramipril and Hoe140 treat-
ment on aortic changes in subtotally nephrec-
tomized rats. Semithin sections (magnification,
1:110). Aortic wall thickness is significantly
higher in untreated (B) and Ramipril 1 Hoe140
(D)-treated SNX compared with controls (A)
and Ramipril-treated SNX (C).
ous studies [4, 15]. To take care of this confounding particularly in view of the fact that Hoe140 affects the
BP-lowering effect of ACEi even in humans [19]. Thefactor, some of the morphological indices were also fac-
tored for body weight. main finding—obliteration of the beneficial effect of
ACEi by B2 receptor blockade—certainly cannot be ex-Blood pressure was measured by tail plethysmography
in slightly anesthetized animals. Therefore, when inter- plained by hypertension as a confounder, since subtotally
nephrectomized rats on Ramipril plus Hoe140 had BPpreting these results it must be kept in mind that small
differences in BP cannot be reliably excluded, as they values well below those in sham-operated controls.
Both Ramipril and Hoe140 are partially eliminatedare demonstrable only by telemetric monitoring [18],
Amann et al: Bradykinin and uremic cardiovascular changes158
Fig. 2. Cumulative frequency of lumen diam-
eters. There is no significant difference in the
cumulative frequency of lumen diameters be-
tween the groups. Symbols are: (r) sham; (j)
SNX; (m) SNX 1 Ramipril; (3) SNX 1
Ramipril 1 Hoe140; (*) SNX 1 Hoe140; (d)
SNX 1 Hoe140 after 4 weeks.
Fig. 3. Individual values and means of car-
diac intercapillary distance. Intercapillary dis-
tance is significantly higher (P , 0.05) in un-
treated and Hoe140-treated SNX than in
sham-operated controls. Treatment with Ram-
ipril alone or in combination with Hoe140 did
not significantly modify intercapillary dis-
tance.
via renal excretion [11, 20], so that a dose reduction was not permit definite conclusions concerning regression.
Nevertheless, in an exploratory study, we assessed thenecessary in the uremic animals. For logistical reasons,
only one dose of Ramipril and Hoe140 was used, how- effects of a delayed Ramipril treatment that started four
weeks after SNX. For logistical reasons, a matched con-ever.
The protocol, that is, treatment starting at the third trol group was not examined.
In this study, a significant increase of left ventricularday postoperatively, addressed the issue of prevention
of structural abnormalities. Our study design thus did mass was seen in SNX rats. In previous studies, LVH
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Fig. 4. Individual values and means of aortic
wall thickness. Mean aortic wall thickness is
significantly higher (P , 0.05) in untreated
and Ramipril 1 Hoe140-treated SNX than
in sham-operated animals and Ramipril-
treated SNX.
could be dissociated from BP, suggesting a role of sys- How the hypothetical effect of Ang II on capillary
temic or local humoral systems [2, 4, 21]. In the present formation is actually mediated is yet unknown. Ang II
study, Hoe140 prevented the beneficial effect of ACEi has opposing actions on microvascular growth [30]: an-
on LVH. This observation argues for an important role giotensin II type 1 (AT1) receptors stimulate and AT2
of bradykinin in the genesis of cardiac hypertrophy. This receptors inhibit endothelial cell [31] and vascular smooth
has also been shown in other animal models, for example, muscle cell (VSMC) proliferation. When these cells that
aortic banding [22], although the role of bradykinin on normally express only AT1 receptors are transfected
cardiac remodeling has remained controversial [23, 24]. with AT2 receptor, the mitogenic action of Ang II in
Kohzuki et al failed to find evidence for a role of kinins vitro is obliterated [32]. We acknowledge that in the
on the cardioprotective effect of cilazapril in spontane- previously mentioned study, the differences of left ven-
ously hypertensive rats with renal ablation [25]. The dis- tricular mass between the groups are a confounding fac-
crepancy with the present results may reflect differences tor. Indeed, we cannot exclude that changes in capillary
in the relative importance of BP elevation for the devel- density are secondary to differences in left ventricular
opment of LVH in the two models. A pathogenetic role mass, and more specific studies are required to exclude
of bradykinin appears plausible in view of reports on this possibility.
local production of bradykinin [26] and bradykinin accu-
Wall thickening of arteriolar and arterial vessels is a
mulation after pretreatment with ACEi in the rat myo-
known feature of uremia [4, 21]. It is independent of BPcardium [27]. Furthermore, B2 receptors had been docu-
since wall thickening is seen even if BP is lowered bymented on rat cardiomyocytes [28].
antihypertensive treatment [21]. There are important dif-Confirming previous results [4, 29], we found reduced
ferences in the reaction of arterioles and large arteries,capillary length density and increased intercapillary dis-
that is, intramyocardial arterioles and the aorta, respec-tance in the hypertrophied myocardium of uremic rats.
tively. As expected, the wall-to-lumen ratio of intramyo-Ramipril treatment alone caused a numerical increase,
cardial arterioles was significantly higher in SNX animalswhich was not statistically significant and which was
[4, 20]. Arteriolar wall thickening was also seen in SHRsomewhat lower after concomitant B2 blockade. Treat-
rats [33]. Although in SHR thickening of mesentericment with the B2 receptor antagonist Hoe140, however,
arterioles was prevented by enalapril, in the previouslyresulted in a further significant decrease of myocardial
mentioned SNX rats, wall thickness of cardiac arteriolescapillary supply, pointing to a potential pathogenetic role
of bradykinin in cardiac capillarization. remained unchanged despite treatment with Ramipril.
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This is particularly important, since Ramipril had caused intramyocardial arteries and the aorta may be due to
the lowering of BP and reduction of LVH. These obser- differences in mediator mechanisms, as hypothesized
vations are in agreement with previous studies in our previously in this article. It is also of interest, however,
laboratory [4] but differ from those of Kakinuma et al that wall thickening of intramyocardial arterioles is the
[34], who found lower wall thickness of intramyocardial result of VSMC hypertrophy [42, 43], whereas thickening
arteries when rats with chronic renal failure caused by of the aortic media is primarily caused by cell hyperplasia
renal artery ligation were treated with ACEi. The ab- [14]. Since the pathogenesis is different, it seems reason-
sence of an effect of ACEi in our experiment was not able to anticipate different susceptibilities to interven-
modified further by concomitant inhibition of B2 recep- tions.
tors. Taken together, the previously mentioned results These results suggest that some of the beneficial effects
argue against a major role of either Ang II or bradykinin of ACEi on cardiovascular structures in experimental
but point to a possible role of ET-1, since significantly renal failure are mediated via accumulation of bradyki-
less thickening of intramyocardial arterioles was noted nin. Unless there are major species differences, this find-
when SNX rats were treated either with a selective ETA ing implies that Ang II receptor antagonists will not
or a nonselective ETA/B receptor antagonist [17]. The duplicate the beneficial effect of ACEi on cardiovascular
heterogenity of vascular remodeling in different vascular structure in uremia. Confirmation or refutation of this
provinces is illustrated by the markedly different findings hypothesis will require direct head-on comparison of
in the aorta. In the SNX rat, aortic wall thickening could these two classes of agents.
be prevented by treatment with Ramipril. The beneficial
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